Drugs are not cutting it: Patient motivations for metabolic and bariatric surgery despite glucagon-like peptide-1 use
Authors:
- Aryaman DassADAryaman Dass
- Stefanie C. RohdeSRStefanie C. Rohde
- Theresa N. WangTWTheresa N. Wang
- Grace F. ChaoGCGrace F. Chao
- Patrick J. SweigertPSPatrick J. Sweigert
Open Access
Abstract
No abstract availableFunding Information
- College of Medicine Office of Research, Ohio State University
- Ohio State University
This publication has 33 references indexed in Scilit:
- Trends in Metabolic and Bariatric Surgery Use During the GLP-1 Receptor Agonist EraJAMA Surgery, 2026
- Combining Medications With Bariatric Surgery to Treat ObesityJAMA, 2026
- Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor AgonistsJAMA Surgery, 2025
- A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?Surgical Endoscopy, 2024
- Obesity Management in AdultsJAMA, 2023
- Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort studySurgical Endoscopy, 2023
- Understanding Racially Diverse Community Member Views of Obesity Stigma and Bariatric SurgeryObesity Surgery, 2022
- Long-Term Results of One Anastomosis Gastric Bypass: a Single Center Experience with a Minimum Follow-Up of 10 YearsObesity Surgery, 2021
- What Is Weight Loss After Bariatric Surgery Expressed in Percentage Total Weight Loss (%TWL)? A Systematic ReviewObesity Surgery, 2021
- Association Between Bariatric Surgery and Long-term SurvivalJAMA, 2015